Leticia Toledo-Sherman
Corporate Officer/Principal en LymphoSign, Inc. .
Cargos activos de Leticia Toledo-Sherman
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Corporate Officer/Principal | 01/08/2004 | - |
Historial de carrera de Leticia Toledo-Sherman
Antiguos cargos conocidos de Leticia Toledo-Sherman.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| MDS Proteomics, Inc. | Corporate Officer/Principal | - | - |
Kinetix Pharmaceuticals, Inc.
 Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Corporate Officer/Principal | - | - |
Formación de Leticia Toledo-Sherman.
| The State University of New York | Doctorate Degree |
Estadísticas
Internacional
| Canadá | 3 |
| Estados Unidos | 3 |
Operativa
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
Sectorial
| Commercial Services | 3 |
| Health Technology | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
Kinetix Pharmaceuticals, Inc.
Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Commercial Services |
| MDS Proteomics, Inc. | Commercial Services |
